AC
AKCA

Amia Capital’s Akcea Therapeutics Inc AKCA Stock Holding History

Amia Capital’s Portfolio AKCA Stock Details AKCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-13,761
Closed -$189K – 39
2020
Q2 		$189K Sell
13,761
-7,576
-36% -$117K 0.16% 35
2020
Q1 		$305K Sell
21,337
-6,880
-24% -$113K 0.27% 28
2019
Q4 		$478K Buy
+28,217
New +$525K 0.14% 34

Other funds holding AKCA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Amia Capital's AKCA Position: Q3 2020 in Review

Amia Capital sold out of Akcea Therapeutics Inc (AKCA) in Q3 2020, closing a stake of 13,761 shares — an estimated $189K sold.

Amia Capital first reported a position in AKCA in Q4 2019 and held it in 3 quarters. The position peaked at $478K in Q4 2019. 98 funds tracked by Wall St. Rank hold AKCA as of Q3 2020.

  • Amia Capital reported no remaining Akcea Therapeutics Inc position as of Q3 2020 after selling out during the quarter.
  • Amia Capital sold 13,761 Akcea Therapeutics Inc shares in Q3 2020, an estimated $189K.
  • Amia Capital first reported a position in Akcea Therapeutics Inc in Q4 2019 and held it in 3 quarters.
  • Amia Capital's Akcea Therapeutics Inc position peaked at $478K in Q4 2019.
  • 98 funds tracked by Wall St. Rank held Akcea Therapeutics Inc as of Q3 2020.

Based on Amia Capital's 13F filing for Q3 2020, filed 16 Nov 2020.